Tarsus

May 11, 2021

•

Mar 31, 2021

Tarsus Q1 2021 Earnings Report

Reported first quarter financial results and provided business and clinical updates.

Key Takeaways

Tarsus Pharmaceuticals reported a net income of $10.4 million for the first quarter of 2021, a significant increase compared to the net loss of $(2.0) million for the same period in 2020. The company's cash and cash equivalents totaled $156.2 million as of March 31, 2021.

Initiated Saturn-2, the second pivotal Phase 3 trial for TP-03 in Demodex blepharitis.

Announced FDA acceptance of IND for TP-05, a novel candidate for Lyme disease prevention.

Presented results of the Atlas study at ARVO 2021, highlighting the impact of Demodex blepharitis.

Strategic partnership with LianBio for TP-03 development and commercialization in Greater China.